Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
AU668160B2 - Preparation useful for prevention and treatment of intestinal infections in animals and human beings - Google Patents
[go: Go Back, main page]

AU668160B2 - Preparation useful for prevention and treatment of intestinal infections in animals and human beings - Google Patents

Preparation useful for prevention and treatment of intestinal infections in animals and human beings Download PDF

Info

Publication number
AU668160B2
AU668160B2 AU39810/93A AU3981093A AU668160B2 AU 668160 B2 AU668160 B2 AU 668160B2 AU 39810/93 A AU39810/93 A AU 39810/93A AU 3981093 A AU3981093 A AU 3981093A AU 668160 B2 AU668160 B2 AU 668160B2
Authority
AU
Australia
Prior art keywords
bacteria
animals
sodium
human beings
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU39810/93A
Other versions
AU3981093A (en
Inventor
Mogens Gjerlov
Jacob Verschoor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmalett AS
Original Assignee
Pharmalett AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmalett AS filed Critical Pharmalett AS
Priority to AU39810/93A priority Critical patent/AU668160B2/en
Publication of AU3981093A publication Critical patent/AU3981093A/en
Application granted granted Critical
Publication of AU668160B2 publication Critical patent/AU668160B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

AUSTRALIA
Patents Act 1990 COMPLETE SPECIFICATION STANDARD PATENT Applicant(s): PHARMALETT DANMARK A/S Invention Title: PREPARATION USEFUL FOR PREVENTION AND TREATMENT OF INTESTINAL INFECTIONS IN ANIMALS AND HUMAN BEINGS
C
C. C C
C
The following statement is a full description of this invention, including the best method of performing i.t known to me/us: PREPARATION USEFUL FOR PREVENTION AND TREATMENT OF INTESTINAL INFECTIONS IN ANIMALS AMD HUMAN BEINGS Background of the Invention It is known that Psyllium Husk (also known as Isphagula Husk), in common with many other compounds, such as charcoal, kaolin, and pectins, is capable of binding bacteria to some extent.
To the best of our knowledge, this is a physical binding, similar to the adsorption of chemicals to the surface of activated charcoal. It is also known that divalent ions may increase the adhesion of bacteria to pectins. In this context, it will be clearly understood that adsorption 15 means adhesion to a surface, as distinct from absorption in which something is absorbed into the interior of the absorbing material. To the best of our knowledge, the prior art contains no description of the above substances being capable of adsorbing very effectively some bacteria 20 in preference to others, with the help of a combination of monovalent ions.
ooo Intestinal Flora Normally, many different types of bacteria are present in 25 the intestinal canal. Some are harmless and are important *o in homeostasis, while others are pathogenic or potentially pathogenic under certain conditions. The pathogenic organisms may be present in the intestinal canal of the host in a "dormant state", and do not become pathogenic until they are exposed to some influence, such as for example stress, change of foodstuffs or virus infection.
Two types of pathogenic bacteria present in the intestinal canal are of particular interest: 1) the invasive bacteria that infiltrate into the blood of the host organisms causing septicaemia, and 2) the toxin producing bacteria, that cause toxaemia.
The coliforms and in particular Entero Toxic E. coli (ETEC) that produce colitoxin are of special interest in the present invention.
An activated ETEC is mobile,'and seeks the internal surface of the intestine and adheres to a receptor on the surface of the intestinal wall where it starts to produce toxin.
It is the toxin that is dangerous as in its presence it is 15 more difficult and sometimes no longer possible for the host animal to retain water in the intestinal canal, nor to absorb water or nourishment therefrom. As a result the animal host will dehydrate and in many cases die. Known agents for treatment of this condition include Diaproff 20 (see U.S. patent 5,038,396).
Standard treatments of ETEC and other undesirable bacteria include prophylaxis by administering small amounts of antibiotics in the feedstuff to control the infection, or 25 to reduce the pH of the intestinal canal by means of various acids administered orally. Improving hygiene is also of assistance.
Alternatively, or in addition to the foregoing, therapeutic doses of antibiotics may be given by injection or orally to kill the undesirable bacteria. However, such administration of antibiotics is not specific to the undesirable bacteria, and will kill all bacteria, including 4 the bacteria normally residing in the intestine which are protective of the host, resulting in further complications.
The Invent ion We have found that administration of Psyllium Husk combined with sodium and potassium ions, is unexpectedly effective in binding ETEC.
Although we do not wish to be limited by any hypothetical or postulated mechanism for the observed beneficial effects, we believe that Psyllium Husk in the presence of sodium and potassium ions selectively adsorbs undesirable bacteria and in particular coliforms such as ETEC from the intestinal contents to such an extent that the solution 15 will be almost totally purified therefrom, while at the *same time the normal intestinal flora are substantially unaffected. Although the addition of either sodium or potassium ions has some effect, we have found that by adding both sodium and potassium ions simultaneously, we 20 achieve a synergistic effect exceeding the additive effective of either sodium or potassium ions independen~tly.
The compositIon of Psyllium Husk containing the said sodium and potassium ions may be administered either dry or suspended in water, and may further be used in combination 25 with other biological, organic or inorganic active substances.
The breaking out of diarrhoea is thus prevented by selective removal of the undesirable bacteria, such as ETEC from the site, leaving the normal flora unaffected, and thus optimwum conditions of growth and continuing heal~ily existence of the animal are secured. The present invention greatly reduces the need for consumntion of antibiotics and by doing so also minimises the attendant problem of the generation of antibiotic resistant bacteria that may be potentially pathogenic under certain conditions.
Detailed Description of the Invention Psyllium Husk, also known as Isphagula Husk, hereinafter referred to as PH, contains mucopolysaccarides which in combination with water form a gel (see British Pharmacopaeia 1980, vl. 2:246-247). The MP consist of a polyxylose backbone with side chains containing galactose, mannose, glucose, fructose, rhamnose and arabinose (see Sandh, J.S. 1981. The gel structure of carbohydrate of Isphagula husk ex Plantago ovata Forsk. Carbohydr. Res.
93:247-259, and Dzuyuba, N.P. et al. 1977, Estab3ishment of S" 15 the qualitative and quantitative composition of the polysaccharide of vegetal material and preparations by physico chemical methods Farm Zh. 32: 56-59). The polyxylose backbones are resistant to breakdown by intestinal bacteria or enzymes, with the exception of 20 Bacteroides ovatus (see Salyers. D. at al. 1978, Breakdown of Psyllium hydrocelloid by Strains of Bacteroides ovatus from the human intestinal tract, Can. J. Mic'obiol. 24: 336-338).
25 Isphagula has been used in the past as a local traditional medicine against diarrhoea (see Singh, B.H. 1940 Indian Med. Gaz.: 733).
More recently it has been shown that PH added to electrolyte glucose mixtures stimulates the absorption of glucose and consequently stimulates rehydration in dehydrated animals and humans patent 5,038,396).
We have found that PH together with a combination of sn'41c 6 and potassium ions is far more effective that PH alone. It is believed that this is due to an improved affinity for pathogens which are selectively adsorbed, avoiding the disadvantages of the prior art.
Examples The bacterial strains used in this study was E. coli K88ab (ETEC strains).
Four solutions were made: Solution PH was made in Nutrient Broth (Oxoid CM) and tap water (1 gram/15 ml).
15 Solution was made as solution however 80 mmol/L sodium was added as sodium chloride.
Solution was made as solution however 15 mmol/L potassium was added as potassium chloride.
Solution was made as solution however 80 mmol/L sodium and 15 mmol/L potassium was added as sodium chloride and potassium chloride.
25 In general bacterial suspensions containing 50 million colony forming units per ml were made.
Qualitative adherence Equal amounts of the solutions and bacterial suspensions were homogenized and incubated aerobically at 37 0
C
0.1 0 C) in a water bath. The suspensions were gently shaken for 15 min. Just before and during incubation samples were taken at regular intervals from the bacteria/solution mixtures.
7 Adherence to PH particles was determined in both native preparations under phase contrast microscope and methyleneblue stained preparations under normal light microscope with 400 and 1000 times magnification (Zeiss, 40 and 100 phase-contrast and standard oil jimersion lenses).
Semi-q-uantitative adherence Centrifugation was used to separate the bacteria-PH mixtures into a precipitation fraction containing bacteria adhered to PH and a supernatant fraction with only free bacteria. The PH-bacteria mixtures were centrifugated (Labofuge GL, radius=150 mm) in 10 ml tubes at 600 rpm for 15 min. Before and after centrifugation the optical density of the mixtures and the supernatants were 15 measured (wavelength 541 nm). The difference in optical :::o:density before and after centrifugation is a semi quiantitative measure for the numbers of bacteria adhered to PH particles.
20 The precipitates were resuspended in the original volumes to measure the optical density. Besides, native and methylene-blue stained preparations were made for (phasecontrast) miscroscopy to verify the findings.
25 Results Qualitative adherence The results showed that the adherence of E. coli K88ab to PH particles started after 2 hours of incubation. The adherence was most pronounced for the mixture containing sodium and potassium ions in comparison with the other mixtures.
After three hours the difference between mixture was even more pronounced. Mixture showed the least I I 8 adherence, mixture and did increase the adherence to some extent. The methylene-blue stained slides confirmed the findings of the native preparations.
Semi-quantitative adherence Table 1. Optical density before and after 3 hours incubation of the ;inxtures the supernatants after centrifugation and the difference between and Before incubation After incubation M S M-S M S M-S *o e SMixture 0.98 0.83 0.15 0.96 0.69 0.27 15 Mixture 1.13 0.97 0.16 1.02 0.51 0.51 Mixture 1.15 0.98 0.17 1.16 0.58 0.58 Mixture 1.05 0.93 0,12 1.10 0.14 0.96 Before and after incubation the optical densities of the 20 mixtures and the supernatants were measured in duplicate.
The results indicate that mixture shows strong adherence capability; the supernatant is almost clear of the ETEC E. coli.
Obviously the combination of sodium ions and po'assium ions strongly enhance the capability of the PH particles to adhere to the bacteria. It is envisaged that this combination can replace antibiotics in a lot of cases, such as in medicated feeds.
It is possible that this combination, by strongly adhering to the bacteria, prevents such bacteria from docking onto I 9 the receptor on the surface of the intestinal wall. This .may be as a result of acting as a receptor analogue.
We do not however wish to be limited by any hypothetical or postulated mechanism for the observed beneficial effects of this combination.
9

Claims (3)

  1. 2. A preparation according to claim 1 wherein the sodium containing substances and potassium containing substances comprise sodium chloride and potassium chloride.
  2. 3. A method of preventing and treating animals or human beings suffering from intestinal infections which 15 comprises administering thereto a preparation according to S* any one of claims 1 to 2. DATED THIS 22ND DAY OF FEBRUARY 1996 PHARMLETT DANMARK A/S O0 By Its Patent Attorneys: S 20 GRIFFITH HACK CO., 1 Fellows Institute of Patent 0 Attorneys of Australia a statvhrordkeepspeciPHARM.OANMARK 22.2 ABSTRACT A preparation useful for prevention and treatment of intestin...l infections in animals and human beings, comprises Psyllium Husk together with sodium and potassium ions, for example in the form of sodium chloride and potassium chloride. 4* 4**4 4 44*4 4*404s 4 4 *4 4 4 4* *444 6*
  3. 4. 4 .4 @4 44 4 4 4. 44 .4 4 0 4%Q* 0 44 4. 4 44 44 4 .44 4 4444 4 4444 44 44 4 .4,4 *4 4 44 0 44
AU39810/93A 1993-05-26 1993-05-26 Preparation useful for prevention and treatment of intestinal infections in animals and human beings Ceased AU668160B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU39810/93A AU668160B2 (en) 1993-05-26 1993-05-26 Preparation useful for prevention and treatment of intestinal infections in animals and human beings

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU39810/93A AU668160B2 (en) 1993-05-26 1993-05-26 Preparation useful for prevention and treatment of intestinal infections in animals and human beings

Publications (2)

Publication Number Publication Date
AU3981093A AU3981093A (en) 1994-12-15
AU668160B2 true AU668160B2 (en) 1996-04-26

Family

ID=3726890

Family Applications (1)

Application Number Title Priority Date Filing Date
AU39810/93A Ceased AU668160B2 (en) 1993-05-26 1993-05-26 Preparation useful for prevention and treatment of intestinal infections in animals and human beings

Country Status (1)

Country Link
AU (1) AU668160B2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2897284A (en) * 1983-06-02 1984-12-06 Ciba-Geigy Ag Easily dispersible dietary fibre product
AU3390584A (en) * 1983-10-03 1985-04-23 Gjerlov Mogens Preparation for rehydrating monogastric animals,including human beings,suffering from diarrhoea and use thereof
AU6086890A (en) * 1989-08-10 1991-02-14 Procter & Gamble Company, The Agglomerated psyllium husk containing edible acid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2897284A (en) * 1983-06-02 1984-12-06 Ciba-Geigy Ag Easily dispersible dietary fibre product
AU3390584A (en) * 1983-10-03 1985-04-23 Gjerlov Mogens Preparation for rehydrating monogastric animals,including human beings,suffering from diarrhoea and use thereof
AU6086890A (en) * 1989-08-10 1991-02-14 Procter & Gamble Company, The Agglomerated psyllium husk containing edible acid

Also Published As

Publication number Publication date
AU3981093A (en) 1994-12-15

Similar Documents

Publication Publication Date Title
Czerucka et al. Experimental effects of Saccharomyces boulardii on diarrheal pathogens
Papini et al. Bafilomycin A1 inhibits Helicobacter pylori‐induced vacuolization of HeLa cells
DE69533593T2 (en) PREPARATIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDER CONTAINING ARABINOGALACTAN AND POLYPHENOLS OF LARIX.
Ramesh et al. Prevention of Clostridium difficile-induced ileocecitis with bacteriophage
US20080089942A1 (en) Use of adsorbent carbon microspheres to treat intestinal bacterial infections
AU590578B2 (en) Treatment of non-ulcer dyspepsia with bismuth salts
CN1117585C (en) Nisin combined with monolaurin with anti-helicobacter activity
EP0623024B1 (en) Pharmaceutical bacteriocin compositions and their use for treating gastrointestinal disorders
Choi et al. Effect of apitherapy in piglets with preweaning diarrhea
CN107259203A (en) Application of trichoderma in preparation of feed and/or preparation for treating or preventing vibrio infection of shrimps
AU668160B2 (en) Preparation useful for prevention and treatment of intestinal infections in animals and human beings
ES2290195T3 (en) USE OF CARBON HYDRATES TO ELIMINATE INTESTINAL INFECTIONS IN ANIMALS.
Yokochi et al. Differential release of smooth-type lipopolysaccharide from Pseudomonas aeruginosa treated with carbapenem antibiotics and its relation to production of tumor necrosis factor alpha and nitric oxide
EP2486943B1 (en) Pharmaceutical composition for use in the prophylaxis and treatment of infectious and non-infectious diarrhoea
Glavin et al. Evidence of “cross-stressor”-induced adaptive gastric cytoprotection
RU2150271C1 (en) Method for treating the cases of chronic prostatitis, gastric and duodenal peptic ulcer
CA2031746C (en) Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria
BR9907126A (en) Compounds and processes for the treatment of bacterial dysentery using antibiotics and toxin-binding oligosaccharide compositions
KR100375342B1 (en) A natural antimicrobial agents for the improvement of gastrointestinal disease.
Rokkas et al. Bismuth: effects on gastritis and peptic ulcer
KR101971572B1 (en) Novel Salmonella Enteritidis specific bacteriophage and antibacterial composition comprising the same
KR20010022739A (en) Fixation inhibitors for helicobacter pylori
Craven Salmonella typhimurium, hydrophobic antibiotics, and the intestinal colonization of broiler chicks
Hofstra et al. A comparative study of the effect of oral treatment with augmentin, amoxycillin and bacampicillin on the faecal flora in mice
WO1994027579A1 (en) Ulcer treating composition